ARC-001
A novel, proprietary, sustained release gel which combines 3 anesthetics (lidocaine, bupivacaine, benzocaine), each with a different onset, potency, and duration of action.
Targeting an efficacy profile that delivers pain relief over 5-7 days with one single dose.
ARC-001: Key Features
Triple Combination
The unique formulation combines benzocaine, lidocaine, and bupivacaine, in an extended release formulation.
Gel Formulation
ARC-001 is administered in a gel;
NOT a pill
NOT an injection
Local Pain Management
Oral surgeons prefer local pain management (versus systemic) whenever possible.
Status
-
Clinical Stage - currently in Phase 1B
-
Preclinical program - successfully completed
-
CMC - manufacturing scaled
-
Investigational New Drug application (IND) approved by FDA
Preclinical
IND
Phase I
Phase II
Phase III
ARC-001